Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid REMS Could Be Linked To CME, FDA Suggests

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committee panel members will weigh in on the value of common educational materials and the metrics for success.

You may also be interested in...



REMS For Opioids, LABAs May Be Driven By PBM "Feedback" Mechanism

Possible contract from FDA would involve assessing whether PBM distribution of safety information to physicians would change prescribing practices.

REMS For Opioids, LABAs May Be Driven By PBM "Feedback" Mechanism

Possible contract from FDA would involve assessing whether PBM distribution of safety information to physicians would change prescribing practices.

FDA's Opioid REMS Proposal Has Narrow Focus On Education

Faced with data gaps, inadequate metrics and the need to maintain access to therapies, FDA takes a narrow approach to addressing long-acting and extended-release opioid abuse and misuse in its proposed Risk Evaluation and Mitigation Strategy for the painkillers

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070933

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel